Abliva AB (publ) (NEVPF)
Abliva AB (publ)
Medicon Village
Scheeletorget 1
Lund 223 81
Sweden
46 4 62 75 62 20
https://abliva.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 6
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Ellen K. Donnelly Ph.D. | Chief Executive Officer | 5.81M | N/D | 1974 |
| Ms. Catharina Jz Johansson | Deputy CEO, CFO & VP of Investor Relations | N/D | N/D | 1967 |
| Dr. Eskil Elmér M.D., Ph.D. | Chief Scientific Officer & VP of Discovery | 247k | N/D | 1970 |
| Ms. Eleonor Åsander Frostner | Communications Officer & Lab Manager | N/D | N/D | 1981 |
| Dr. Magnus Hansson | Chief Medical Officer and VP of Preclinical & Clinical Development | N/D | N/D | 1976 |
| Mr. Dag Nesse | Vice President of Clinical Operations | N/D | N/D | 1966 |
| Dr. Lars Vedin | Consultant | N/D | N/D | N/D |
Descripción
Abliva AB (publ) discovers and develops medicines for the treatment of mitochondrial disease in Sweden. The company is developing KL1333 that is in Phase 2 clinical trial to treat chronic fatigue and myopathy in genetically confirmed adult patients with primary mitochondrial disease; and NV354, which has completed preclinical development for the treatment of mitochondrial disease with neurologic complications. It has a licensing and collaboration agreement with Owl Therapeutics for NeuroSTAT for the treatment of traumatic brain injury; and Yungjin Pharm on the clinical development of the KL1333, as well as Isomerase, Children's Hospital of Philadelphia, Newcastle University and University College London, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Gestión corporativa
La calificación ISS Governance QuickScore de Abliva AB (publ) a partir del 1 de junio de 2024 es 6. Las puntuaciones principales son Auditoría: 7; Junta: 2; Derechos del accionista: 4; Compensación: 10.
